{"id":"W4412461070","doi":"10.1016/s2352-3026(25)00163-2","title":"Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Open label; Refractory (planetary science); Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001029151,0.0006773203,0.004008747,0.0003529364,0.0003236693,0.000120426,0.0003710641,0.000321672,0.00004475755],"category_scores_gemma":[0.005593919,0.0003518,0.00007654741,0.0005478144,0.0006285579,0.0002467518,0.0003273276,0.0007851985,0.000005522689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001537871,"about_ca_system_score_gemma":0.0005086482,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001476257,"about_ca_topic_score_gemma":0.002742228,"domain_scores_codex":[0.994837,0.001075891,0.001361002,0.001157828,0.00060549,0.0009628121],"domain_scores_gemma":[0.9899117,0.007330055,0.0008120699,0.001310379,0.0002892044,0.000346582],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8356673,0.003479724,0.1483408,0.00006133103,0.002593929,0.001782843,0.0004530233,9.493776e-7,0.00006924748,0.00002779799,0.0003945931,0.0071285],"study_design_scores_gemma":[0.8712431,0.009048402,0.1167702,0.0003323621,0.001052486,0.00008337036,0.0002440472,0.0004213665,0.0001909556,0.00003380022,0.0002433792,0.0003365417],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834604,0.0005490542,0.000046147,0.001616665,0.0002630407,0.0129601,0.0003327264,0.00009710527,0.0006747745],"genre_scores_gemma":[0.994009,0.0002026092,0.003149669,0.0003960921,0.00005129439,0.001197637,0.0006536496,0.0000643585,0.0002756483],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03557584,"threshold_uncertainty_score":0.9998934,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04989390241174046,"score_gpt":0.3510920310800825,"score_spread":0.301198128668342,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}